Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05239793 | RECRUITING | Chronic Obstructive Pulmonary Disease

Electronic Cigarette-derived Oxidants and Cardiopulmonary Effects
Sponsor:

Milton S. Hershey Medical Center

Information provided by (Responsible Party):

Rebecca Bascom

Brief Summary:

This is a pilot study on the impact of switching from cigarettes to Electronic Cigarettes (EC) on disease-related clinical symptoms and biomarkers of harm in smokers with preexisting Chronic Obstructive Pulmonary Disease (COPD). The researchers hypothesize that the smokers who switch to EC completely or significantly will experience reduced COPD symptoms, risks of exacerbations, and decreased levels of oxidative stress and inflammation.

Condition or disease

Chronic Obstructive Pulmonary Disease

Intervention/treatment

NJOY e-cigarette

Phase

EARLY_PHASE1

Detailed Description:

Smokers with COPD have a higher pack-year history and nicotine dependence compared to regular smokers as exemplified by the relatively large proportion of patients diagnosed with COPD that continue to smoke (95%). This is a translational project which addresses the changing profile of tobacco product use in the United States (US) and the need for data regarding toxicity pathways for new nicotine products such as EC. In particular it focuses on critical scientific and clinically relevant gaps relating to oxidants in EC and their potential long-term cardiopulmonary effects. The study will obtain new information regarding the potential cardiopulmonary toxicity resulting from exposure to EC-derived oxidants that may lead to long-term disease development.

Study Type : INTERVENTIONAL
Estimated Enrollment : 30 participants
Masking : NONE
Primary Purpose : OTHER
Official Title : Translational Studies on Electronic Cigarette-derived Oxidants and Their Long-term Cardiopulmonary Effects
Actual Study Start Date : 2022-11-22
Estimated Primary Completion Date : 2025-06-30
Estimated Study Completion Date : 2025-06-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 21 Years to 74 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Mild to moderate COPD
  • * Smokes a popular brand of cigarette
  • * Willing to use an e-cigarette to reduce cigarette smoking down to 75% of their daily baseline cigarette use
  • * Ability to read, write and understand English
  • * Ability to provide informed consent and attend study visits
Exclusion Criteria
  • * History of active, chronic drug abuse or alcohol abuse problems
  • * Actively changing smoking behavior
  • * Unwilling or unable to provide blood samples
  • * Pregnant, planning to become pregnant, or nursing
  • * Use of tobacco products other than cigarettes in the past 30 days
  • * Recent history (\< 6 months) of myocardial infarction (MI)
  • * Any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or drug therapy within the past year. Antiarrhythmic drugs include amiodarone, flecainide, IV ibutilide, IV lidocaine, procainamide, propafenone, quinidine, tocainide
  • * Hospitalization for heart failure (NY Heart Association III or IV) within the past year
  • * Uncontrolled hypertension
  • * Known allergy to vegetable glycerin and propylene glycol
  • * History of seizures or medications to prevent seizures
Electronic Cigarette-derived Oxidants and Cardiopulmonary Effects

Location Details

NCT05239793

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Pennsylvania

Penn State Health Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States, 17033